Human CD20 (Research Grade Rituximab Biosimilar) Antibody, R&D Systems™

CD20

Flow Cytometry 0.25 ug/10^6 cells, CyTOF-ready

Monoclonal

Supernatant

Human

B1, B-lymphocyte antigen CD20, B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, Bp35MGC3969, CD20, CD20 antigen, CD20 receptor, CD20S7, CVID5, LEU-16, Leukocyte surface antigen Leu-16, Ly-44, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1, MS4A1, MS4A2, S7

Human CD20

Primary

Reconstitute at 0.5 mg/mL in sterile PBS.

Detects Human CD20 based on Rituximab therapeutic antibody. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Rituximab. This product is for research use only.

Hu2

Flow Cytometry, CyTOF

Unconjugated

Human

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS.

931

IgG1

Protein A or G purified from cell culture supernatant

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.